Late-Onset Immune-Mediated Adverse Effects after Poly-L-Lactic Acid Injection in Non-HIV Patients: Clinical Findings and Long-Term Follow-Up

被引:25
作者
Alijotas-Reig, Jaume [1 ,2 ]
Garcia-Gimenez, Victor [1 ]
Vilardell-Tarres, Miquel [2 ]
机构
[1] Vall Hebron Univ Hosp, CIBBIM Nanomed, Mol Biol & Biochem Res Ctr Nanomed, Aging Basic Res Grp, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Dept Internal Med 1, Barcelona, Spain
关键词
Poly-L-lactic acid injection; Lipo-atrophy; Dermal filler; complications; DERMAL FILLERS; POLYLACTIC ACID; FACIAL LIPOATROPHY; HYALURONIC-ACID; SARCOIDOSIS; GRANULOMAS; EFFICACY; NODULES; SAFETY;
D O I
10.1159/000243804
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
Background: It has been thought that poly-L-lactic acid (PLLA) injections do not have inflammatory side effects. Recent evidence shows that local/regional/systemic delayed adverse effects may appear with its use. Objective: To evaluate the clinical complaints, treatment response and long-term follow-up of non-HIV patients with delayed immune-mediated adverse effects related to PLLA injections. Methods: Prospective, case series study of 10 patients with delayed adverse effects related to PLLA injections. The inclusion criterion was defined as the onset at least 6 months after PLLA use, with 1 or more of the following clinical signs: oedema, skin induration, swelling/tender nodules with or without discharge of pus or filler material. Several systemic manifestations were also included. Patients with immediate side effects were excluded. Patients underwent clinical management and long-term follow-up. Results: The average latency period to the onset of symptoms was 19.2 months (range: 6-60). Tender, inflammatory nodules and facial oedema were commonly seen. One case presented a systemic granulomatous disorder as a complication. After 50.2 months of average follow-up (range: 38-78), 5 patients are in remission, 4 have recurrent bouts and the last case has been lost to follow-up. Conclusion: Although infrequently, local and/or regional and/or systemic delayed and recurrent granulomatous reactions may complicate PLLA gel injections. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:303 / 308
页数:6
相关论文
共 35 条
[1]
Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature [J].
Alijotas-Reig, J. ;
Garda-Gimenez, V. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (02) :150-161
[2]
Delayed immune-mediated adverse effects of polyalkylimide dermal fillers -: Clinical findings and long-term follow-up [J].
Alijotas-Reig, Jaume ;
Garcia-Gimenez, Victor ;
Miro-Mur, Francesc ;
Vilardell-Tarres, Miquel .
ARCHIVES OF DERMATOLOGY, 2008, 144 (05) :637-642
[3]
Delayed Immune-Mediated Adverse Effects Related to Polyacrylamide Dermal Fillers: Clinical Findings, Management, and Follow-Up [J].
Alijotas-Reig, Jaume ;
Garcia-Gimenez, Victor ;
Miro-Mur, Francesc ;
Vilardell-Tarres, Miquel .
DERMATOLOGIC SURGERY, 2009, 35 (01) :360-366
[4]
Andre P, 2005, J Cosmet Laser Ther, V7, P171, DOI 10.1080/14764170500344393
[5]
[Anonymous], TXB RHEUMATOLOGY
[6]
Development of sarcoidosis in cosmetic tattoos [J].
Antonovich, DD ;
Callen, JP .
ARCHIVES OF DERMATOLOGY, 2005, 141 (07) :869-872
[7]
Clinicopathologic Correlation of Delayed-Onset Periorbital Poly-l-Lactic Acid Nodules [J].
Beer, Kenneth .
DERMATOLOGIC SURGERY, 2009, 35 (01) :399-402
[8]
RESORPTION RATE, ROUTE OF ELIMINATION, AND ULTRASTRUCTURE OF IMPLANT SITE OF POLYLACTIC ACID IN ABDOMINAL-WALL OF RAT [J].
BRADY, JM ;
CUTRIGHT, DE ;
MILLER, RA ;
BATTISTONE, GC ;
HUNSUCK, EE .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1973, 7 (02) :155-166
[9]
Allopurinol: A therapeutic alternative for disseminated cutaneous sarcoidosis [J].
Brechtel, B ;
Haas, N ;
Henz, BM ;
Kolde, G .
BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 (02) :307-309
[10]
Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy [J].
Burgess, CM ;
Quiroga, RM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) :233-239